XFOR - X4 Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
10.32
+0.05 (+0.49%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close10.27
Open10.35
Bid8.88 x 1000
Ask13.50 x 1000
Day's Range10.20 - 10.83
52 Week Range9.36 - 23.93
Volume139,924
Avg. Volume85,006
Market Cap128.55M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.19
Earnings DateNov 06, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.14
  • Business Wire

    X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor in Combination with Ibrutinib for the Treatment of Waldenström’s Macroglobulinemia (WM)

    X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the initiation of a Phase 1b clinical trial of mavorixafor (X4P-001) in combination with ibrutinib (Imbruvica®) for the treatment of Waldenström’s macroglobulinemia (WM), a rare form of non-Hodgkin’s lymphoma. Mavorixafor, X4’s lead therapeutic candidate, is a potential first-in-class, once-daily, oral, small molecule antagonist of chemokine receptor CXCR4.

  • Street Watch: Top Analysts Make Moves on 3 Buy-Rated Stocks
    TipRanks

    Street Watch: Top Analysts Make Moves on 3 Buy-Rated Stocks

    Onward and upward the market goes, with December providing further cheer as new record highs for the S&P 500 were notched in the last week. Giddy from 2019’s riches and ready to bring in the New Year, the optimism on the Street, following a brief slump, has been renewed.While analysts are divided as to whether the next year can follow this one’s record breaking run, one thing looks certain; investors will still be on the lookout for the right addition to their portfolio.TipRanks - a company that tracks and measures the performance of analysts - has an instrument that comes in handy here. The Daily Stock Ratings tool allows a user to see what stocks are hot and, yes, what stocks are not. Analysts’ ratings and their performances are displayed, too, further helping the intrepid investor make the right decision.Let’s have a look, then, at 3 Buy-rated stocks a number of the Street’s leading analysts recently pulled the trigger on.Stemline Therapeutics Inc (STML)With a focus on developing and bringing to market novel oncology therapies, Stemline Therapeutics has recently been turning heads on the Street.The New York based biotech has several therapies in the pipeline, but already has one on the market. Elzonris is used to treat a rare blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN), and was approved by the FDA in December 2018 for the treatment of adults and pediatric patients over 2 years old. The drug is currently in clinical trials to assess further indications.Cantor Fitzgerald’s Alethia Young calls Elzonris a "pipeline in a product" and believes the biotech is undervalued. Stemline’s market cap is currently $555.4 million, and Young expects sales from Elzonris for BPDCN (sans maintenance therapy) to be in the region of $150 million by 2025. We’re talking about just the US here. Furthermore, the 5-star analyst thinks the possible expansion of Elzonris into the BPDCN maintenance setting in 2021 could, by 2029, result in US sales of $223M. Young maintains that as "as investors take notice of progress in the label expansion opportunities”, the next 12 months should see Stemline’s share price take off.Accordingly, Young initiated coverage on Stemline with an Overweight rating and set a price target of $18. This implies upside potential of 62% over the next 12 months. (To watch Young’s track record, click here)The Cantor analyst’s bullish thesis is mirrored by that of the Street’s. All 5 analysts tracked over the last three months rate the stock a Buy, and therefore, Stemline has a Strong Buy consensus rating. An average price target of $22.75 outstrips Young’s target and indicates gains of 105% could be in the cards. (See Stemline stock analysis on TipRanks) X4 Pharmaceuticals Inc (XFOR)The biotech sector’s recent upturn in the market hasn’t, unfortunately, had any effect on X4 Pharmaceuticals. The rare disease focused biotech has had a rough year in the market, and its share price is down by 21% year-to-date. The word on the Street, though, is that this is all about to change.The company has several drugs in the pipeline, but its lead candidate is mavorixafor (X4P-001), currently in Phase 3 development for the treatment of WHIM syndrome. The rare, inherited condition is an immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. Designated orphan status by the FDA in 2018, the drug is also in development for several other conditions, including Waldenström’s macroglobulinemia (WM).Roth Capital’s Zegbeh Jallah highlights XFOR’s “well experienced team” which includes Dr. Renato Skerlj, who developed the first CXCR4 antagonist (plerixafor), as making it a stand-out. Jallah also bases his bullish thesis on a “strong conviction around the clinical and commercial outlook” of mavorixafor, and “a robust pipeline of optimized CXCR4 modulators that could offer improved benefits across a broader range of diseases.” As a result, the analyst initiated coverage of X4 with a Buy rating and a price target of $20, indicating handsome upside potential of 82%. (To watch Jallah’s track record, click here)A fellow analyst praising XFOR is Oppenheimer’s Leland Gershell. The 5-star analyst expects the drug to gain approval for WHIM syndrome and remains "cautiously optimistic" about its part to play in Waldenstrom's macroglobulinemia. Leland initiated coverage with an Outperform rating and a price target of $20, too. (To watch Gershell’s track record, click here)3 other analysts have chipped in with a take on X4 over the last three months and all have reached the same conclusion: Buy. Therefore, the rare disease specialist has a Strong Buy consensus rating. The average price target of $20.25 could provide investors with gains of 84% over the next 12 months. (See X4 Pharmaceuticals stock analysis on TipRanks) See also: 3 “Strong Buy” Energy Stocks with Electric Upside PotentialiMedia Brands Inc (IMBI)Moving on from the biotech industry, we encounter a fellow struggler. Although in a completely different industry, multiplatform commerce company iMedia Brands hasn’t had much joy in 2019, either. Languishing in the doldrums, the company has a year-to-date loss of 7%.That being said, iMedia has an expanding portfolio of shopping television networks and new media businesses including ShopHQ and iMedia Web Services. November saw new additions to the list, too. The first, Float Left Interactive, an OTT (over the top) and TVE (TV everywhere) service provider, has launched a string of OTT apps and counts NBC, Comcast and CBS among its clients. The second, J.W. Hulme, is a maker of leather bags and accessories, and will get its own programming on ShopHQ's cable channel.So, with the new developments in place, is now the right time to get in on iMedia? It is according to D.A. Davidson’s Tom Forte. The 5-star analyst forecasts iMedia revenue to grow by 3% per year over the next three years and projects that by 2022, the company’s EBITDA margin will expand by almost 500 basis points to 3.1%.Furthermore, with LaVenta, the company’s new omni-channel, Spanish language, television shopping network launching in Q1 2020, Forte acknowledges iMedia’s potential for expansion outside the US.To this end, Forte initiated coverage on the interactive media company with a Buy rating, alongside a price target of $10. The bullish target indicates upside potential of a whopping 170%. (To watch Forte’s track record, click here)iMedia currently has only 1 other analyst assessing the company’s 12-month potential, but he happens to be a vocal fan, too. Lake Street’s Mark Argento reckons the next year could see iMedia’s share price reach $15, which lends itself to a massive 305% increase from the current price. (To watch Argento’s track record, click here)Put together, the media company has a Moderate Buy consensus rating and an average price target of $12.50. Potentially, then, investors could be lining their pockets with a 237% gain next year. (See iMedia price targets and analyst ratings on TipRanks)

  • Benzinga

    Benzinga Pro's Top 5 Stocks To Watch For Mon., Dec. 23, 2019: SRPT, ROK, CNSL, DPW, XFOR

    Benzinga Pro's Stocks To Watch For Monday Sarepta Therapeutics (SRPT)  - Shares were up about 9% Monday morning following news of a partnership with  Roche (RRHBY)  for its investigational micro-dystrophin ...

  • Hedge Funds Staying Clear Of X4 Pharmaceuticals, Inc. (XFOR)
    Insider Monkey

    Hedge Funds Staying Clear Of X4 Pharmaceuticals, Inc. (XFOR)

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • X4 Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
    Zacks

    X4 Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

    X4 Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

  • X4 Pharmaceuticals Enters Oversold Territory
    Zacks

    X4 Pharmaceuticals Enters Oversold Territory

    X4 Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Business Wire

    X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that, on November 26, 2019, the Compensation Committee of X4’s Board of Directors issued an inducement award to a new employee under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement award consists of options to purchase an aggregate of 55,000 shares of X4’s common stock and was granted as an inducement material to the new employee entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4).

  • TEST Business Wire Releases

    X4 Pharmaceuticals Prices $65 Million Public Offering of Common Stock and Class B Warrants

    X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases, announced today the pricing of its previously announced underwritten public offering of 3,666,667 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 1,750,000 shares of common stock, and accompanying Class B warrants to purchase 5,416,667 shares of its common stock (or, for investors who so choose, pre-funded warrants to purchase shares of common stock) at a price to the public of $12.00 per share and accompanying Class B warrant (or $11.999 per pre-funded warrant and accompanying Class B warrant). X4’s gross proceeds from this offering are expected to be approximately $65.0 million, before deducting underwriting discounts and estimated offering expenses. All of the securities in the offering are being sold by X4. The offering is expected to close on or about November 29, 2019, subject to customary closing conditions.

  • Benzinga

    The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...

  • Business Wire

    X4 Pharmaceuticals Announces Proposed Public Offering

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics for the treatment of rare diseases, announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and Class B warrants to purchase its common stock. All of the securities in the offering will be sold by X4.

  • Business Wire

    X4 Pharmaceuticals to Present at Stifel 2019 Healthcare Conference

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that management will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19th, 2019 at 8:35 am EST in New York, NY. X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. X4’s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC), with several patients remaining on therapy over 12 months beyond the primary endpoint.

  • Business Wire

    X4 Pharmaceuticals Receives Breakthrough Therapy Designation from the FDA for Mavorixafor for the Treatment of WHIM Syndrome

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for mavorixafor (X4P-001) for the treatment of adult patients with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene.

  • Business Wire

    X4 Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Business Highlights

    Received orphan drug designation from the European Commission for mavorixafor for treatment of WHIM Syndrome

  • ACCESSWIRE

    X4 Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 7, 2019 / X4 Pharmaceuticals, Inc. (NASDAQ: XFOR ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on November 7, 2019 at ...

  • Business Wire

    X4 Pharmaceuticals Initiates Phase 1b Clinical Trial of Mavorixafor for the Treatment of Severe Congenital Neutropenia

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the initiation of a Phase 1b clinical trial of mavorixafor (X4P-001) for the treatment of Severe Congenital Neutropenia (SCN), a group of rare blood disorders characterized by abnormally low levels of neutrophils. The Phase 1b trial is a 14-day, proof-of-concept trial designed to assess the safety and tolerability of daily, oral mavorixafor in participants with SCN and other selected congenital neutropenia disorders. In addition, the trial will evaluate the neutrophil response in this patient population as an independent agent or in combination with granulocyte-colony stimulating factor (G-CSF).

  • Business Wire

    X4 Pharmaceuticals Appoints Derek Meisner, J.D., as General Counsel

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the appointment of Derek Meisner, J.D., as General Counsel. Mr. Meisner brings more than two decades of experience providing counsel to public and private companies across key legal and operational functions, including regulatory compliance, debt and equity financings, mergers and acquisitions, strategic partnerships and corporate governance. “As a strategic and solution-oriented executive, Derek brings his broad legal and business experience to support X4’s high growth trajectory and is an important and welcome addition to our team,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.

  • Business Wire

    X4 Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Provide Recent Business Highlights on November 7, 2019

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced that it will report its financial results for the third quarter ended September 30, 2019 before market open on Thursday, November 7, 2019. The Company will host a conference call and webcast on the same day at 8:00 a.m. ET to discuss these financial results and business highlights. The conference call can be accessed by dialing (866) 721-7655 from the United States or (409) 216-0009 internationally, followed by the conference ID: 4081686.

  • Business Wire

    X4 Pharmaceuticals Reports Positive Data from Phase 2a Trial of Mavorixafor in Combination with Axitinib in Advanced Clear Cell Renal Cell Carcinoma Patients

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced positive results from the Phase 2a portion of its open-label Phase 1/2 clinical trial of mavorixafor (X4P-001) in combination with axitinib (Inlyta®) in patients with advanced clear cell renal cell carcinoma (ccRCC). Combination therapy with mavorixafor and approved tyrosine kinase inhibitor (TKI) axitinib was generally well tolerated with a manageable safety profile and demonstrated clinical improvement with encouraging median progression free survival (mPFS) in a heavily pretreated advanced ccRCC patient population. Of the 65 patients in the trial, 49 patients (or 75%) received mavorixafor + axitinib as a third- to ninth-line therapy, having received between two and eight prior therapies with a TKI, immuno-oncology (IO) agent, or other systemic therapy.